Yutaka Matsuda
Oncology Research Intelligence & Modality Intelligence Lead Astellas Pharma
Seminars
ADCs have become increasingly sophisticated. Payload selection, linker design, and conjugation chemistries are critical to enhancing efficacy, addressing clinical resistance, and improving the therapeutic index. Join this workshop to explore emerging payload classes, advances in linker design, next-generation conjugation technologies, and dual-payload strategies across ADCs and beyond.
This workshop will explore advances in conjugation chemistry and their implications for ADC design, drug-to-antibody ratio (DAR), and therapeutic properties.
Key Topics include:
- Unlocking novel conjugation, linker design and payloads with established and novel mechanisms of action
- Unravelling dual-payload ADCs, and bioconjugates designs beyond ADCs